265 related articles for article (PubMed ID: 19480963)
1. Anti-HPV vaccination: a review of recent economic data for Italy.
Mennini FS; Costa S; Favato G; Picardo M
Vaccine; 2009 May; 27 Suppl 1():A54-61. PubMed ID: 19480963
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
3. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
[TBL] [Abstract][Full Text] [Related]
4. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
7. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
8. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
Dasbach EJ; Elbasha EH; Insinga RP
Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
Dee A; Howell F
Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
[TBL] [Abstract][Full Text] [Related]
10. Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study.
Favato G; Baio G; Capone A; Marcellusi A; Costa S; Garganese G; Picardo M; Drummond M; Jonsson B; Scambia G; Zweifel P; Mennini FS
Med Care; 2012 Dec; 50(12):1076-85. PubMed ID: 22922435
[TBL] [Abstract][Full Text] [Related]
11. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
[TBL] [Abstract][Full Text] [Related]
13. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
[TBL] [Abstract][Full Text] [Related]
14. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
16. A brief history of economic evaluation for human papillomavirus vaccination policy.
Beutels P; Jit M
Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of papillomavirus-associated cancer].
Signorelli C
Ann Ig; 2008; 20(3 Suppl 1):65-74. PubMed ID: 18773608
[TBL] [Abstract][Full Text] [Related]
18. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
Westra TA; Daemen T; Postma MJ; Wilschut JC
Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
[TBL] [Abstract][Full Text] [Related]
19. "Anti-HPV vaccination: a review of recent economic data for Italy.".
Garattini L; Casadei G
Vaccine; 2009 Aug; 27(38):5171. PubMed ID: 19596421
[No Abstract] [Full Text] [Related]
20. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
